BioCentury | Feb 24, 2014
Finance

Microcap M&A

Microcap M&A Mast Therapeutics Inc. (NYSE-M:MSTX) doesn't view M&A as a surefire way to scale up, but the microcap hopes its second opportunistic deal in three years can add enough value to attract investors and...
BC Week In Review | Mar 25, 2013
Clinical News

ANX-514: Development discontinued

Mast Therapeutics (formerly Adventrx Pharmaceuticals Inc. ) discontinued development of ANX-514 last year to focus on MST-188 . In October 2011, Adventrx said FDA agreed on the design of the open-label pivotal (Study 514-02) trial comparing ANX-514...
BC Week In Review | Feb 18, 2013
Clinical News

Purified poloxamer 188: QT/QTc study started

Adventrx began a 4-way crossover, double-blind, placebo- and active-controlled thorough QT/QTc trial to evaluate 2 doses of ANX-188 in about 60 healthy volunteers. ANX-188 is in the Phase III EPIC trial in about 388 pediatric...
BC Week In Review | Feb 11, 2013
Clinical News

Purified poloxamer 188: Phase III started

Adventrx began the double-blind, placebo-controlled Phase III EPIC trial to evaluate 100 mg/kg IV ANX-188 for 1 hour followed by 30 mg/kg for up to 48 hours in 388 patients ages 8-17 years who have...
BC Week In Review | Jan 14, 2013
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif.   Business: Cancer, Infectious, Hematology   Transitioned: Brandi Roberts to CFO and SVP from VP of finance  ...
BC Week In Review | Nov 5, 2012
Clinical News

ANX-188: Phase III start

This quarter, Adventrx will begin a double-blind, placebo-controlled Phase III trial evaluating ANX-188 in 388 patients with sickle cell disease ages 8-17 years and who are experiencing acute pain typical of vaso-occlusive crisis. Adventrx Pharmaceuticals...
BC Week In Review | Aug 20, 2012
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif.   Business: Cancer, Infectious, Hematology   Hired: Santosh Vetticaden as CMO and SVP, formerly SVP and chief medical and development officer of Cubist Pharmaceuticals Inc.  ...
BC Week In Review | Mar 19, 2012
Financial News

Adventrx financial update

Adventrx filed a shelf registration covering the sale of up to $150 million of its securities. The company, which closed Friday at $0.64, has 47.7 million shares outstanding. Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif....
BioCentury | Jan 2, 2012
Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...
BC Week In Review | Nov 14, 2011
Financial News

Adventrx completes follow-on

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif.   Business: Cancer, Infectious   Date completed: 11/11/11   Type: Follow-on   Raised: $17 million   Units: 21.3 million   Price: $0.80 (unit)   Shares after offering: 47.7...
Items per page:
1 - 10 of 166
BioCentury | Feb 24, 2014
Finance

Microcap M&A

Microcap M&A Mast Therapeutics Inc. (NYSE-M:MSTX) doesn't view M&A as a surefire way to scale up, but the microcap hopes its second opportunistic deal in three years can add enough value to attract investors and...
BC Week In Review | Mar 25, 2013
Clinical News

ANX-514: Development discontinued

Mast Therapeutics (formerly Adventrx Pharmaceuticals Inc. ) discontinued development of ANX-514 last year to focus on MST-188 . In October 2011, Adventrx said FDA agreed on the design of the open-label pivotal (Study 514-02) trial comparing ANX-514...
BC Week In Review | Feb 18, 2013
Clinical News

Purified poloxamer 188: QT/QTc study started

Adventrx began a 4-way crossover, double-blind, placebo- and active-controlled thorough QT/QTc trial to evaluate 2 doses of ANX-188 in about 60 healthy volunteers. ANX-188 is in the Phase III EPIC trial in about 388 pediatric...
BC Week In Review | Feb 11, 2013
Clinical News

Purified poloxamer 188: Phase III started

Adventrx began the double-blind, placebo-controlled Phase III EPIC trial to evaluate 100 mg/kg IV ANX-188 for 1 hour followed by 30 mg/kg for up to 48 hours in 388 patients ages 8-17 years who have...
BC Week In Review | Jan 14, 2013
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif.   Business: Cancer, Infectious, Hematology   Transitioned: Brandi Roberts to CFO and SVP from VP of finance  ...
BC Week In Review | Nov 5, 2012
Clinical News

ANX-188: Phase III start

This quarter, Adventrx will begin a double-blind, placebo-controlled Phase III trial evaluating ANX-188 in 388 patients with sickle cell disease ages 8-17 years and who are experiencing acute pain typical of vaso-occlusive crisis. Adventrx Pharmaceuticals...
BC Week In Review | Aug 20, 2012
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif.   Business: Cancer, Infectious, Hematology   Hired: Santosh Vetticaden as CMO and SVP, formerly SVP and chief medical and development officer of Cubist Pharmaceuticals Inc.  ...
BC Week In Review | Mar 19, 2012
Financial News

Adventrx financial update

Adventrx filed a shelf registration covering the sale of up to $150 million of its securities. The company, which closed Friday at $0.64, has 47.7 million shares outstanding. Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif....
BioCentury | Jan 2, 2012
Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...
BC Week In Review | Nov 14, 2011
Financial News

Adventrx completes follow-on

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX), San Diego, Calif.   Business: Cancer, Infectious   Date completed: 11/11/11   Type: Follow-on   Raised: $17 million   Units: 21.3 million   Price: $0.80 (unit)   Shares after offering: 47.7...
Items per page:
1 - 10 of 166